XML 41 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Long-Term Debt - Additional Information (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Aug. 27, 2019
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Sep. 18, 2020
Debt Instrument [Line Items]              
Long-term debt   $ 10,000,000   $ 10,000,000   $ 10,000,000  
Series C Convertible Preferred Stock              
Debt Instrument [Line Items]              
Number of preferred stock shares initially exercisable upon funding of first tranche term loan             23,122
Lender Warrant              
Debt Instrument [Line Items]              
Warrant to purchase number of shares of common stock upon completion of IPO   23,122   23,122      
Lender Warrant | Series C Convertible Preferred Stock              
Debt Instrument [Line Items]              
Warrant exercise price per share   $ 10.812   $ 10.812      
Warrant expiration date       Aug. 27, 2029      
Percentage of preferred shares issuable on aggregate term loans upon exercise of warrant       2.50%      
Number of preferred stock shares initially exercisable upon funding of first tranche term loan   117,924   117,924      
Fair value of liabilities   $ 200,000   $ 200,000      
Term Loans              
Debt Instrument [Line Items]              
Loan agreement date Aug. 27, 2019            
Long-term debt   $ 10,000,000   $ 10,000,000   10,000,000  
Debt instrument, interest rate terms       The Term Loans bear interest at a floating annual rate equal to the greater of (i) the prime rate used by the Lender plus 2.0% (5.25% and 6.75% at September 30, 2020 and December 31, 2019, respectively), and (ii) 7.25%.      
Debt instrument, payment terms       The monthly payments are interest-only until September 1, 2022. Subsequent to the interest-only period, the Term Loans will be payable in equal monthly installments of principal plus accrued and unpaid interest, through the maturity date of September 1, 2023 or, in the event the Fourth Tranche is funded in full, September 1, 2024 (the “Term Loan Maturity Date”).      
Debt instrument, frequency of periodic payment       monthly      
Debt instrument, final payment fee percentage   5.25%   5.25%      
Debt instrument, final payment fee   $ 500,000   $ 500,000   $ 500,000  
Debt instrument, prepayment fee percentage   3.00%   3.00%   3.00%  
Debt instrument, subjective acceleration clause       The Loan Agreement includes customary affirmative and negative covenants and also includes standard events of default, including an event of default based on the occurrence of a material adverse event, and a default under any agreement with a third party resulting in a right of such third party to accelerate the maturity of any debt in excess of $0.3 million.      
Debt instrument, acceleration of maturity of debt, threshold amount   $ 300,000   $ 300,000      
Debt instrument, covenant compliance       As of September 30, 2020 and December 31, 2019, the Company was in compliance with all applicable covenants under the Loan Agreement.      
Debt issuance costs   300,000   $ 300,000      
Debt interest expense   300,000 $ 100,000 800,000 $ 100,000    
Debt discount amortization   100,000 $ 23,000 200,000 $ 23,000    
Accrued interest   $ 100,000   $ 100,000   $ 100,000  
Term Loans | Prime Rate              
Debt Instrument [Line Items]              
Debt instrument, basis spread on variable rate       2.00%      
Debt instrument, variable rate       5.25%   6.75%  
Term Loans | Minimum              
Debt Instrument [Line Items]              
Debt instrument, variable rate       7.25%      
Term Loans | Maximum              
Debt Instrument [Line Items]              
Debt instrument, prepayment fee percentage   3.00%   3.00%      
First Tranche Term Loan              
Debt Instrument [Line Items]              
Long-term debt $ 10,000,000            
Debt instrument, maturity date       Sep. 01, 2023      
Fourth Tranche Term Loan              
Debt Instrument [Line Items]              
Additional borrowing capacity $ 15,000,000            
Expiration date Dec. 31, 2020            
Additional borrowing capacity, description       may borrow up to an additional $15.0 million in a fourth tranche at the Company’s option through December 31, 2020, subject to (i) achievement of certain clinical milestones and (ii) receipt of at least $70.0 million of net proceeds from either a preferred equity financing or an underwritten initial public offering.      
Threshold net proceeds from preferred equity financing or underwritten initial public offering to borrow additional term loan $ 70,000,000            
Debt instrument, maturity date       Sep. 01, 2024